HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 P.m. Eastern Time
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Thursday May 9, 2024 at 4:30 p.m. Eastern time
HeartBeam AI Combined With Vectorcardiography Delivers Equivalent Performance To 12-lead ECG
HeartBeam Presents Positive Results on Its Artificial Intelligence Capabilities for Detecting Arrhythmias
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company's Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly
Heartbeam Price Target Maintained With a $8.00/Share by Benchmark
Heartbeam Price Target Maintained With a $8.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target
Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:BEAT) with a Speculative Buy and maintains $8 price target.
HeartBeam Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 279.15% Benchmark → $8 Reiterates Speculative Buy → Speculative Buy 11/16/2023 279.15% Benchmar
NVFY, BEAT and NTRB Are Among Pre Market Gainers
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2023 Earnings Call Transcript
Q4 2023 Heartbeam Inc Earnings Call
Earnings Call Summary | HeartBeam(BEAT.US) Q4 2023 Earnings Conference
The following is a summary of the HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript:Financial Performance:HeartBeam ended 2023 with cash and cash equivalents totaling $16.2 million, allowing ope
HeartBeam Reports Q4 Results
HeartBeam Q4 2023 GAAP EPS $(0.13), Inline
HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate.
Heartbeam 4Q Loss/Shr 72c >BEAT
Heartbeam 4Q Loss/Shr 72c >BEAT
Press Release: HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results -- First Patients Enrolled in Pivotal Study Evaluating AIMIGo(TM) System for Synthesizing a 12-Lead ECG -- Ongoing
SmartCardia Strengthens U.S. Board With Addition of Veteran Cardiac Device Leader Ken Nelson
LAUSANNE, Switzerland, March 19, 2024 /PRNewswire/ -- SmartCardia, which recently received FDA clearance for its 7-lead real-time ECG monitoring patch and cloud platform, announced today the addition
A Preview Of HeartBeam's Earnings
HeartBeam (NASDAQ:BEAT) is set to give its latest quarterly earnings report on Wednesday, 2024-03-20. Here's what investors need to know before the announcement.Analysts estimate that HeartBeam will r
First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing a 12-Lead ECG
VALID-ECG Study will Form the Basis of the Company's Upcoming FDA 510(k) Submission HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized
What's Going On With Heartbeam (BEAT) Stock?
Heartbeam Inc (NASDAQ:BEAT) shares are trading higher by 3.5% to $2.35 Tuesday, pulling back following the session high of $2.70. The earlier move higher came despite a lack of company-specific news f
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (
HeartBeam Receives Two New US Patents for Its Core Cardiac Monitoring Technology
Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the
No Data